ASIT biotech


Market Cap€4m

Last Close €0.18

ASIT biotech is restructuring after the failure of its lead product.

More ASIT biotech content >

Investment summary

Edison Investment Research is terminating coverage on Abacus Health Products (ABCS), ADL Bionatur (BNT), ASIT Biotech (ASIT), GAME Digital (GMD), International Stem Cell Corporation (ISCO), Powerhouse Energy Group (PHE), Windar Photonics (WPHO). Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Dec
Revenue (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2017A 0.0 (12.0) (12.0) (93.6) N/A N/A
2018A 0.0 (12.8) (14.3) (85.7) N/A N/A
2019E N/A N/A N/A N/A N/A N/A
2020E N/A N/A N/A N/A N/A N/A
Industry outlook

Reported gp-ASIT+ Phase III allergy data showed a statistically proven but inadequate clinical response.

Last updated on 04/09/2020
Content on ASIT biotech
ASIT biotech – Statistically significant clinical insignificance
Healthcare | research Update | 26 November 2019
ASIT biotech research image
ASIT biotech – Building to a crescendo
Healthcare | research Update | 19 September 2019
ASIT biotech research image
Executive interview – ASIT Biotech
Healthcare | Edison TV | 23 July 2019
View more
Register to receive research on ASIT biotech as it is published
Share price graph
Balance sheet
Forecast net debt (€m) N/A
Forecast gearing ratio (%) N/A
Price performance
Actual 8.4 (23.3) (85.2)
Relative* 8.7 (20.1) (84.0)
52-week high/low €2.6/€0.2
*% relative to local index
Key management
Michel Baijot CEO
Frank Hazevoets CFO
Yves Desiront CFO